NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-.
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].
Show detailsBibliographic details: Wang Z, Xu J, Nie W, Huang G, Tang J, Guan X. Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis. European Journal of Clinical Pharmacology 2014; 70(2): 225-231. [PubMed: 24150533]
Abstract
BACKGROUND: Regorafenib is a novel multikinase inhibitor approved for use in metastatic colorectal cancer (mCRC) and locally advanced gastrointestinal stromal tumors (GISTs). Hypertension is one of the major adverse events of this agent, but to date the incidence and risk of hypertension with regorafenib have not been systematically investigated. We have conducted a systematic review and meta-analysis of published clinical trials to determine its overall incidence and risk.
METHODS: PubMed, Web of Science and abstracts presented at the American Society of Clinical Oncology annual meetings were searched to identify relevant studies published up to September 9, 2013. Eligible studies were prospective phase II or III clinical trials using regorafenib in cancer patients with data on hypertension available. The incidence and relative risk (RR) of hypertension were calculated using a random-effects model.
RESULTS: Data from a total of 1,069 patients (regorafenib n = 750; controls n = 319) from five clinical trials were included for analysis. The overall incidence of all-grade and high-grade hypertension were 44.4 % [95 % confidence interval (CI) 30.8-59.0 %) and 12.5 % (95 % CI 5.2-27.1 %), respectively. The use of regorafenib in cancer patients was associated with a significantly increased risk of all-grade (RR 3.76, 95 % CI 2.35-5.99) and high-grade (RR, 8.39, 95 % CI 3.10-22.71) hypertension. The risk might vary with tumor types (P = 0.000).
CONCLUSIONS: Patients with cancer receiving regorafenib have a significantly higher risk of developing hypertension. Close monitoring and appropriate management of this hypertension are strongly recommended.
- Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.[Invest New Drugs. 2013]Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.Belum VR, Wu S, Lacouture ME. Invest New Drugs. 2013 Aug; 31(4):1078-86. Epub 2013 May 23.
- Review Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.[Ann Pharmacother. 2013]Review Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.Crona DJ, Keisler MD, Walko CM. Ann Pharmacother. 2013 Dec; 47(12):1685-96. Epub 2013 Nov 1.
- Review Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.[Lancet Oncol. 2008]Review Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Lancet Oncol. 2008 Feb; 9(2):117-23. Epub 2008 Jan 24.
- Review Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.[Crit Rev Oncol Hematol. 2014]Review Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.Abdel-Rahman O, Fouad M. Crit Rev Oncol Hematol. 2014 Dec; 92(3):194-207. Epub 2014 Jul 1.
- Review Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.[J Hum Hypertens. 2013]Review Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.Funakoshi T, Latif A, Galsky MD. J Hum Hypertens. 2013 Oct; 27(10):601-11. Epub 2013 May 2.
- Risk of hypertension with regorafenib in cancer patients: a systematic review an...Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis - Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews
Your browsing activity is empty.
Activity recording is turned off.
See more...